The National Institute of Health and Clinical Excellence (NICE) has issued an Appraisal Consultation Document for Inhaled Insulin (Exubera)® for Type I and Type II Diabetes.
This Appraisal is a preliminary recommendation and subject to change before publication however this document states that NICE do not recommend Inhaled Insulin for use on the NHS unless it is part of a clinical trial.
Inhaled Insulin has many limitations in general use as discussed already. In addition to these clinical concerns this new product is likely to cost more at £1,100 per patient per year compared to £300 for injected insulin.
Action: Clinicians involved in the treatment of diabetes may be asked about this product by patients and should be aware of current information.
|« Ibuprofen Isomer||Innovo Insulin Pen Discontinued »|